Clinical trials: Prostate Cancer Detection
Kidney Cancers, Prostate Cancer
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
The COMFORT study will evaluate an artificial intelligence-based platform developed to support the clinical assessment of kidney and prostate cancer.
- Trial name
- COMFORT (NCT07888322)
- Testing
- Medical Reading, AI assisted Medical reading
- Where
- 6 sites in Germany, Greece and 2 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Prostate Cancer Diagnosis
Can Needle Size Improve Cancer Detection Rate of Transperineal MRI Target Prostate Biopsy Without Affecting Side Effects?
Differences in terms of diagnostic capability and side effects related to the needle caliber used for prostate biopsy sampling in patients with suspected prostate cancer
- Trial name
- TARGET (NCT06420115)
- Testing
- different needle size for prostate biopsy
- Where
- Italy
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- University Hospital Padova
Metastatic Prostate Cancer
Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer
This research is being done to see if an investigational radioactive drug called 18F-DCFBC can help us find cancer that has spread (metastatic disease) from its original site in people who have cancer in their prostate to other…
- Trial name
- NCT01815515
- Testing
- 18F-DCFBC
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Carcinoma
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
The goal of this project is to detect prostate cancer cells, shed in voided urine, using the optical imaging method developed in our laboratory, which targets VPAC1 and STEAP1 receptors expressed on prostate cancer cells and…
- Trial name
- NCT04788277
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic…
- Trial name
- NCT03800784
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
The primary objective of this study is to evaluate the performance of HR-TRUS in detection of prostate cancer lesions relative to whole mount section after radical prostatectomy as the reference.
- Trial name
- EXACTVU (NCT03679819)
- Testing
- HR-TRUS
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Institut Paoli-Calmettes
Risk of Breast Cancer, Risk of Gynaecological Cancer
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease.
- Conditions
- Risk of Breast Cancer, Risk of Gynaecological Cancer, Risk of Colorectal Cancer, Risk of Upper Gastrointestinal Cancers
- Trial name
- LEAH (NCT06907095)
- Testing
- biological samples
- Where
- France
- Volunteers
- 5,909 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer
Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
Background: Ferumoxytol is an approved iron replacement therapy agent that has some potential for use as a contrast agent in imaging studies of the lymph system, especially involving lymph nodes that have been affected by cancer.
- Trial name
- NCT01296139
- Testing
- Ferumoxytol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor
This trial aims to develop and validate the urinary multimarker sensor which can measure trace amounts of biomarkers from naturally voided urine in men referred with clinical suspicion of prostate cancer who have had no prior…
- Trial name
- NCT04825002
- Testing
- Urinary multimarker sensor
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Asan Medical Center
Prostate Cancer
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have…
- Trial name
- ProGRESS (NCT05926102)
- Testing
- Precision screening intervention, Usual care
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Prostate Cancer, Prostatic Neoplasms
Multiparametric Ultrasound Imaging in Prostate Cancer
Rationale: The current limitations in prostate cancer diagnostics, due to lack of accuracy of the available techniques, lead to over- and undertreatment for a significant fraction of patients with prostate cancer.
- Trial name
- NCT03101176
- Testing
- SonoVue
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Elevated PSA, Prostate Cancer
Functional and Morphologic MRI in the Detection of Prostate Cancer in Patients With Prior Negative Biopsy
Prostate specific antigen (PSA) and digital rectal exam (DRE) are used to screen for prostate cancer. Patients with abnormal DRE or elevated PSA undergo transrectal ultrasound guided biopsy (TRUS-Bx).
- Trial name
- NCT00242060
- Testing
- MRI
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
This phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in detecting the spread of cancer to the bones (bone metastasis) in patients with prostate cancer and increased…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Trial name
- NCT04928820
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases
The objective of this trial is to assess the value of 18F-choline PET/CT for the detection of regional lymph node metastases from prostate cancer.
- Trial name
- PROPET (NCT00670527)
- Testing
- [18F] Fluorocholine PET/CT
- Where
- Denmark
- Volunteers
- 205 people
- Sponsor
- Odense University Hospital
Prostate Cancer
BR55 in Prostate Cancer: an Exploratory Clinical Trial
The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging.
- Trial name
- NCT01253213
- Testing
- BR55
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Bracco Diagnostics, Inc
Prostate Cancer
Artificial Intelligence and Radiologists at Prostate Cancer Detection in MRI: The PI-CAI Challenge
The PI-CAI challenge aims to validate the diagnostic performance of artificial intelligence (AI) and radiologists at clinically significant prostate cancer (csPCa) detection/diagnosis in MRI, with respect to histopathology and…
- Trial name
- NCT05489341
- Testing
- Histopathology and Magnetic Resonance Imaging with Follow-Up, Histopathology and Magnetic Resonance Imaging
- Where
- Netherlands
- Volunteers
- 10,207 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Prostate Cancer
MyProstateScore Equivalency With and Without DRE
The purpose of the study is to quantify the concordance of MPS results between first-catch urine samples collected post-DRE and those collected without a DRE.
- Trial name
- NCT05700370
- Testing
- MyProstateScore
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- LynxDx
Neoplasm, Prostate
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
Background: Currently, patients suspected of having prostate cancer undergo ultrasound-guided systematic biopsies of the prostate.
- Trial name
- PSMA-DOCS (NCT03149861)
- Testing
- PET/MR-ultrasound guided Fusion biopsy, Systemic TRUS guided biopsy
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer Detection
Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
The study is a prospective, multi-center, single cohort study involving up to 10 urological clinics in the US. After provision of informed consent, up to 20 mL of whole blood will be collected from each subject.
- Trial name
- PRIME (NCT07543757)
- Testing
- Proclarix
- Where
- 7 sites in United States
- Volunteers
- 500 people
- Sponsor
- Sequenom, Inc.
Prostate Cancer
Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer
In Europe, prostate cancer (PCa) is the most common solid neoplasm, with an incidence rate of 214 cases per 1000 men, outnumbering lung and colorectal cancer.
- Trial name
- NCT01672411
- Where
- Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Of Perugia